The copper-binding tripeptide GHK and its complex GHK-Cu have been studied for their influence on collagen, fibroblast activity, and the remodelling of the skin’s extracellular matrix.
This research area examines how the copper-binding tripeptide glycyl-L-histidyl-L-lysine (GHK), and its copper(II) complex GHK-Cu, influence collagen production, fibroblast behaviour, and extracellular-matrix (ECM) remodelling in skin. GHK occurs naturally in human plasma, and studies report that its levels decline with age, prompting interest in its role as an endogenous signal peptide during tissue repair. In vitro work with cultured dermal fibroblasts suggests that GHK-Cu can stimulate synthesis of collagen (including types I, III and IV), elastin, glycosaminoglycans and small proteoglycans such as decorin, with dose-dependent responses often reported at low nanomolar concentrations.
Research also indicates modulation of matrix metalloproteinases (MMP-1, MMP-2) and their tissue inhibitors (TIMP-1, TIMP-2), which together govern the balance between ECM deposition and breakdown. Genomic analyses suggest GHK can alter expression of a broad set of genes linked to tissue regeneration, antioxidant defence, and immune regulation. In animal wound models, injections of GHK-Cu were associated with increased granulation tissue, type I collagen and glycosaminoglycan accumulation. These findings are preclinical and in vitro in nature, and describe mechanistic biology rather than established clinical outcomes.
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.